AOD-9604 weight loss claims: what the science actually shows

What did @californialeggs actually say?

Honestly? It's hard to know. The transcript from this video is nearly unintelligible, likely the result of auto-captioning a Spanish-language video. The caption says "Comparto para que no te pase" ("I'm sharing so this doesn't happen to you"), which suggests a cautionary personal experience. The hashtags point to AOD peptides and a "peptide journey." But the actual spoken content, as captured, reads like machine noise.

What we can reasonably infer is that the creator is sharing something about a product experience, possibly related to AOD (likely AOD-9604, a modified fragment of human growth hormone). References to checking a product and something going wrong are present in the garbled text. Without a clean transcript, we are working with context clues, not direct quotes. That itself is a problem worth naming.

Does the science back this up?

AOD-9604 has a limited but real research footprint. The evidence base is thin and mostly old. A Phase IIb trial (Ng et al., 2000, Obesity Research) showed modest fat-loss effects in obese adults, but the compound never made it through Phase III trials for obesity. That pipeline died over two decades ago.

Since then, AOD-9604 has migrated into the compounded peptide market, where it is often marketed for fat loss and metabolic benefits. The U.S. FDA removed AOD-9604 from its list of bulk substances approved for compounding in 2015, which significantly limits its legal availability through telehealth channels in the United States. No large randomized controlled trials have validated its use in the doses or combinations currently popular in wellness communities. The science does not keep up with the hype, and the hype is moving fast on TikTok.

What did they get wrong (or right)?

Because the transcript is a transcription failure rather than a clear set of claims, it is impossible to fact-check specific statements with precision. That is not a pass for the video. The framing of the caption, a warning about something that happened to the creator, combined with product-checking language, suggests the video may be cautioning viewers about product quality, sourcing, or a bad experience. If that is the case, that is actually responsible content.

What is harder to credit is the broader context: the hashtag "peptidejourney" and AOD promotion on TikTok exists mostly in a space where sourcing is unregulated, dosing advice comes from influencers rather than clinicians, and follow-up care is nonexistent. Even well-intentioned content participates in that ecosystem. The creator may have had a genuine cautionary message. Without a readable transcript, we cannot confirm or deny it.

What should you actually know?

AOD-9604 is not FDA-approved for any indication. It is not the same as semaglutide, tirzepatide, or any approved weight-loss medication. Compounded peptides sold online vary widely in purity, concentration, and sterility. A 2022 review (Rafalski et al., 2022, Frontiers in Pharmacology) noted that peptide therapeutics sourced outside regulated pharmacy channels carry real contamination and misdosing risks.

If you are considering peptide therapy, the starting point is a licensed clinician who can order labs, review your history, and monitor outcomes. A TikTok video, including this one, is not a substitute for that. The "I'm sharing so this doesn't happen to you" framing is actually a reasonable instinct. The problem is that 9,800 viewers may take away different lessons depending on what they already believe about peptides.

• AOD-9604 was studied for obesity but failed to reach FDA approval after Phase III.
• The FDA removed AOD-9604 from approved compounding substances in 2015.
• Compounded peptides are not equivalent to approved pharmaceuticals in purity or standardization.
• Personal experience content about peptides on TikTok rarely includes clinical context or dosing supervision.
• A cautionary framing does not automatically make peptide content safe or accurate.